OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on commercial products developed with its LentiVector® platform. In the six months to end June 2017, Novartis made considerable progress towards approval of CTL019, improving sentiment for OXB which supplies vector essential for its manufacture. Post-period, a new deal was signed with Novartis, with OXB potentially receiving >$100m over three years. The cash position @31st July was £22.1m.